<div id="content" class="col-md-12" style="">
<div data-drupal-messages-fallback="" class="hidden"/><div id="block-medsites-page-title" class="widget block">
<h1><span property="schema:name">Post-Liver Transplant Management</span>
</h1>
</div>
<div id="block-medsites-content" class="widget block">
<article data-history-node-id="2548" role="article" about="/commodorecompendium/post-liver-transplant-management" typeof="schema:WebPage">
<div>
<div property="schema:text" class="field field--name-body field--type-text-with-summary field--label-hidden field__item"><table class="TableGrid8" style="width:100.0%; border-collapse:collapse; border:none" width="100%">
<tbody>
<tr>
<td style="border-bottom:1px solid black; width:100%; padding:0in 7px 0in 0in; height:12px; border-top:2px double black; border-right:none; border-left:none">
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><b><span style="font-size:12.0pt"><span style="font-family:Palatino">Post Liver Transplant Management – Lauren Evers Carlini, Gabe Sandoval</span></span></b></span></span></span></p>
</td>
</tr>
</tbody>
</table>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Background</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Immunosuppression (IS): pts typically start out on 2-3 immunosuppression medications, including a calcineurin inhibitor (CNI, tacrolimus or cyclosporine), a glucocorticoid (prednisone), and potentially another agent (i.e., mycophenolate mofetil). Decreased over time, as long as there is no evidence of rejection</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">ID ppx:  PJP (trimethoprim-sulfamethoxazole), CMV if at risk for reactivation (valganciclovir or ganciclovir; highest risk is D+/R-; typically 3-6 months based on when ppx is stopped), and candida (fluconazole) for weeks to months after LT.</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Screening for malignancy: post-transplant pts are at increased risk of malignancy due to IS. Pts must follow all standard cancer screening guidelines, as well as annual dermatology evaluation for skin cancers (high incidence of SCC).</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Avoid live vaccines after transplantation; pts are given a list and in general admitted pts are not given vaccinations in house. </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">When admitted, LT recipients should have home IS meds continued (unless otherwise advised by attending or transplant pharmacist), with daily trough levels. See below. </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Hepatology should always be consulted for these pts</span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Transplant medications</span></span></span></span></span></p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Tacrolimus:</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Mainstay of post-transplant IS</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Doses should be timed for 0600/1800 while admitted, regardless of home schedule</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Pts need tacro levels QAM at 0500 while hospitalized(specific order in Epic); </span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Goal levels (generally):</span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">0-3 months post-transplant: 8-10 ng/mL</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">3-12 months: 6-8 ng/mL</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">&gt;12 months: 3-6 ng/mL</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Side effects: Nephrotoxicity, neurotoxicity (HA, confusion, seizure, paresthesia’s, tremor; more common w/tacrolimus vs cyclosporine), N/V/D, hyperkalemia, hypomagnesemia, hyperglycemia, hyperuricemia, alopecia, HTN, HLD</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Note: transplant pharmacists (on weekdays) are your go-to resource for adjusting dosage and goal levels; you will not be making these decisions independently</span></span></span></span></span></li>
</ul>
<p> </p>
<p><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Cyclosporine:</span></span></span></span></span></p>
<ul>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Used in pts transplanted before tacrolimus was available, pts unable to tolerate tacrolimus, or those with a contraindication to tacrolimus</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Doses should be timed for 0600/1800 while admitted, regardless of home schedule</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Pts need cyclosporine levels QAM at 0500 while hospitalized (specific order in Epic)</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Goal levels (generally):</span></span></span></span></span>
<ul style="list-style-type:circle">
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">0-3 months post-transplant: 150-200 ng/mL</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">3-6 months: 150 ng/mL</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">6-12 months: 100 ng/mL</span></span></span></span></span></li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">&gt;12 months: 60-100 ng/mL</span></span></span></span></span></li>
</ul>
</li>
<li><span style="font-size:11pt"><span style="line-height:normal"><span style="font-family:Calibri,sans-serif"><span style="font-size:12.0pt"><span style="font-family:Palatino">Side effects: Nephrotoxicity, hypomagnesemia, hyperglycemia, neurotoxicity (HA, tremors, paresthesia, seizure), gingival hyperplasia, hirsutism, malignancy (lymphoma), HTN, HLD</span></span></span></span></span></li>
</ul>
</div>
</div>
</article>
</div>
</div>